AN ACT to amend Tennessee Code Annotated, Title 4; Title 63 and Title 68, relative to the state uterine fibroids commission.
SB1969 establishes the State Uterine Fibroids Commission within Tennessee law and places it in the Department of Health’s administrative structure. The commission would be an 11-member body made up of representatives from nursing, primary care, higher education, hospital and health systems, two individuals diagnosed with uterine fibroids, polycystic ovary syndrome, or endometriosis, and two legislative members. Members would serve staggered terms, the commission would meet quarterly, adopt bylaws, elect a chair, and operate without compensation, though legislators could receive standard per diem and travel reimbursement.
The commission’s core duties are advisory and research-oriented. It would evaluate existing efforts related to uterine fibroids and related conditions, review state regulations and policies affecting prevention, treatment, and care, support reporting on these conditions, hold an annual public hearing, and make recommendations to the governor, the Department of Health, and the General Assembly. It must also submit an annual report to the relevant Senate and House committees by December 31 each year. The bill amends Tennessee’s statutory list of state entities to include the new commission and takes effect immediately upon becoming law.
The bill adds a new chapter to Title 63 creating a permanent state commission focused on uterine fibroids and related gynecological conditions, and it also amends Title 4 to recognize the commission among state boards and commissions. It does not create direct benefits, mandates, or coverage requirements for patients, but it does require the Department of Health to provide staff support and establishes an ongoing reporting and policy-review mechanism that could influence future public health policy, research priorities, and legislative proposals affecting women’s health.
The available vote history suggests the bill was received favorably at least in the Senate Government Operations Committee, where it was recommended for passage by a 6-0 vote and referred onward to the Senate Health and Welfare Committee. No committee transcript was provided, so there is no recorded debate to indicate opposition or support beyond the unanimous committee action. Overall, the bill appears to have been treated as a public-health and women’s-health measure with broad initial support.
No specific objections are documented in the provided materials. Potential points of discussion, if raised later in the process, could include the need for a new commission versus using existing health bodies, the inclusion of industry representatives alongside patients and clinicians, and whether the commission’s advisory role is sufficiently targeted to produce measurable policy changes. The bill’s structure suggests a consensus-oriented approach, with patient advocates, health professionals, and legislators all represented.